Audience: Physicians, nurse practitioners, physician assistants, pharmacists and nurses

This course is designed for primary care providers who wish to start treating their HCV-positive patients on-site, rather than referring them to specialists. It includes the latest treatment considerations, drug interactions, treating patients with substance use disorders, as well as information on prior authorization, patient education and adherence. The didactic half-day will be followed by a half-day clinical case discussion on HCV mono-infected patients. Faculty include Jay Kostman, MD (Medical Director, John Bell Health Center, Philadelphia FIGHT Community Health Centers). This program is sponsored in collaboration with the Viral Hepatitis Program, Division of Disease Control, Philadelphia Department of Public Health. 

Didactic Half-Day: Wednesday, November 9, 2022 7:45 am ET - 12:30 pm ET

Half-Day Clinical Case Discussion: Wednesday, November 16, 2022 7:45 am ET - 12:30 pm ET

If you have questions about the course, call Susan Thompson, 215.246.5324.

CME Program Code: 22254

 TARGET AUDIENCE: Physicians, nurse practitioners, pharmacists, advanced practice nurses, nurses, physician assistants and staff who provide HCV care

 LEARNING OBJECTIVES: Participants will be able to:

• Describe medical management of HCV
• Identify when to initiate change in medications and manage complications
• Apply current research for patients with a substance use disorder

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Drexel University College of Medicine and the MidAtlantic AIDS Education and Training Center of the Health Federation of Philadelphia.  The Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 4.5 AMA PRA

Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AOA: This program is eligible for 4.5 credits in Category 2A of the American Osteopathic Association.

FACULTY DISCLOSURE STATEMENT 

It is the policy of Drexel University College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs.  Speakers at continuing medical education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients).  Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker’s commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.       

 FACULTY DISCLOSURES: Susan Thompson, BS has no conflicts to disclose.  Jay Kostman, MD, is on the speaker bureaus of Abbvie and Gilead Sciences.  David Koren, PharmD, BCPS, AAHIVP is on the advisory board for Gilead Sciences, ViiV, and Thera Technologies and is an independent contractor for Abbvie and Thera Technologies. Jody Gilmore, ANP-BC is on the speaker bureau of Gilead Sciences and Abbvie.  All three faculty will attest that clinical recommendations are evidence-based and free of commercial bias.

PLANNING COMMITTEE DISCLOSURES: James Dean, MD, Yelena Galkin, MD, Caroline Johnson, MD, Jennifer Kolker, MPH, and Debra D’Alessandro, MPH have no commercial relationships to disclose. 

Supported by a grant from the Health Resources and Services Administration (HRSA),

HIV/AIDS Bureau, Office of Program Support,

No. U1OHA29295